Jung M
Department of Pharmaceutical Chemistry, Westfälische Wilhelms-Universität Münster, Germany.
Mini Rev Med Chem. 2001 Nov;1(4):399-407. doi: 10.2174/1389557013406747.
In antibody directed enzyme prodrug therapy (ADEPT) an antibody bound enzyme is targeted to tumor cells. This allows for selective activation of a nontoxic prodrug to a cytotoxic agent at the tumor site for cancer therapy. Site-selective prodrug activation results in reduced side effects in remote tissue. This article reviews ADEPT with emphasis on the chemical viewpoint and recent developments.
在抗体导向酶前药疗法（ADEPT）中，一种与抗体结合的酶被靶向输送到肿瘤细胞。这使得一种无毒前药能够在肿瘤部位选择性地激活为细胞毒性药物，用于癌症治疗。前药的位点选择性激活可减少远处组织的副作用。本文从化学角度并结合近期进展对抗体导向酶前药疗法进行综述。
